Evidence map›Paper›PMID 40056277›Full record

ArticleInternational journal of clinical oncology2025

High incidence of immune checkpoint inhibitor-induced pneumonitis in patients with non-small cell lung cancer and interstitial pneumonia, regardless of honeycomb lung or forced vital capacity: results from a multicenter retrospective study.

Yuriko Ishida, Satoshi Ikeda, Toshiyuki Harada, Jun Sakakibara-Konishi, Keiki Yokoo, Hajime Kikuchi, Tae Iwasawa, Toshihiro Misumi, Satoshi Konno, Takashi Ogura

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuriko IshidaDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka Higashi Kanazawaku, Yokohama, Kanagawa, 236-0051, Japan.
Satoshi IkedaDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka Higashi Kanazawaku, Yokohama, Kanagawa, 236-0051, Japan. isatoshi0112@gmail.com.ORCID http://orcid.org/0000-0001-5203-7911
Toshiyuki HaradaCenter for Respiratory Diseases, JCHO Hokkaido Hospital, Sapporo, Hokkaido, Japan.
Jun Sakakibara-KonishiDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Keiki YokooDepartment of Respiratory Medicine, Teine Keijinkai Hospital, Sapporo, Hokkaido, Japan.
Hajime KikuchiDepartment of Respiratory Medicine, Obihiro Kosei Hospital, Obihiro, Hokkaido, Japan.
Tae IwasawaDepartment of Radiology, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan.
Toshihiro MisumiDepartment of Data Science, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Satoshi KonnoDepartment of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
Takashi OguraDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1, Tomioka Higashi Kanazawaku, Yokohama, Kanagawa, 236-0051, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInterstitial pneumonia (IP) is a common comorbidity with poor prognosis in patients with non-small cell lung cancer (NSCLC) and a risk factor for immune checkpoint inhibitor (ICI)-induced pneumonitis. This study aimed to assess the incidence, severity, and risk factors of ICI-induced pneumonitis in patients with NSCLC and idiopathic IP.

methodsThis multicenter, retrospective study involved patients with advanced or recurrent NSCLC and comorbid idiopathic IP and receiving ICI monotherapy as the second or subsequent line. A board-certified radiologist centrally reviewed all computed tomography images at baseline and at the onset of pneumonitis. Logistic regression analysis with clinical, laboratory, and radiological variables was used to examine the risk factors for pneumonitis.

resultsThis study included 65 patients with a median age of 71 years, 98.5% of whom had a smoking history. Three ICIs were used and a median of three cycles. Honeycomb lung was present in 23.1% of the patients, and the median % forced vital capacity (FVC) was 95.0%. Notably, 23.1% of the patients exhibited all-grade pneumonitis and 15.4% exhibited grade ≥ 3 pneumonitis. No significant risk factors for pneumonitis were identified after univariate logistic regression analysis. The incidence and severity of ICI-induced pneumonitis did not differ between patients with and without honeycomb lung or with FVC ≥ 80% versus < 80%, respectively.

conclusionIn this retrospective analysis of patients with NSCLC, the risk of ICI-induced pneumonitis did not differ based on radiologic patterns of comorbid IP, presence or absence of honeycomb lung, or pulmonary function tests.

Indexed as

Carcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung Diseases, InterstitialLung NeoplasmsPneumoniaAgedAged, 80 and overFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsTomography, X-Ray ComputedVital CapacityImmune Checkpoint InhibitorsHoneycomb lungImmune checkpoint inhibitorInterstitial pneumoniaNon-small cell lung cancer

Identifiers

PMID40056277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.